Cargando…

Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue

Neurological disorders (NDs) comprise a heterogeneous group of conditions that affect the function of the nervous system. Often incurable, NDs have profound and detrimental consequences on the affected individuals’ lives. NDs have complex etiologies but commonly feature altered gene expression and d...

Descripción completa

Detalles Bibliográficos
Autores principales: Janowski, Marcin, Milewska, Małgorzata, Zare, Peyman, Pękowska, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399958/
https://www.ncbi.nlm.nih.gov/pubmed/34451862
http://dx.doi.org/10.3390/ph14080765
_version_ 1783745199888924672
author Janowski, Marcin
Milewska, Małgorzata
Zare, Peyman
Pękowska, Aleksandra
author_facet Janowski, Marcin
Milewska, Małgorzata
Zare, Peyman
Pękowska, Aleksandra
author_sort Janowski, Marcin
collection PubMed
description Neurological disorders (NDs) comprise a heterogeneous group of conditions that affect the function of the nervous system. Often incurable, NDs have profound and detrimental consequences on the affected individuals’ lives. NDs have complex etiologies but commonly feature altered gene expression and dysfunctions of the essential chromatin-modifying factors. Hence, compounds that target DNA and histone modification pathways, the so-called epidrugs, constitute promising tools to treat NDs. Yet, targeting the entire epigenome might reveal insufficient to modify a chosen gene expression or even unnecessary and detrimental to the patients’ health. New technologies hold a promise to expand the clinical toolkit in the fight against NDs. (Epi)genome engineering using designer nucleases, including CRISPR-Cas9 and TALENs, can potentially help restore the correct gene expression patterns by targeting a defined gene or pathway, both genetically and epigenetically, with minimal off-target activity. Here, we review the implication of epigenetic machinery in NDs. We outline syndromes caused by mutations in chromatin-modifying enzymes and discuss the functional consequences of mutations in regulatory DNA in NDs. We review the approaches that allow modifying the (epi)genome, including tools based on TALENs and CRISPR-Cas9 technologies, and we highlight how these new strategies could potentially change clinical practices in the treatment of NDs.
format Online
Article
Text
id pubmed-8399958
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83999582021-08-29 Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue Janowski, Marcin Milewska, Małgorzata Zare, Peyman Pękowska, Aleksandra Pharmaceuticals (Basel) Review Neurological disorders (NDs) comprise a heterogeneous group of conditions that affect the function of the nervous system. Often incurable, NDs have profound and detrimental consequences on the affected individuals’ lives. NDs have complex etiologies but commonly feature altered gene expression and dysfunctions of the essential chromatin-modifying factors. Hence, compounds that target DNA and histone modification pathways, the so-called epidrugs, constitute promising tools to treat NDs. Yet, targeting the entire epigenome might reveal insufficient to modify a chosen gene expression or even unnecessary and detrimental to the patients’ health. New technologies hold a promise to expand the clinical toolkit in the fight against NDs. (Epi)genome engineering using designer nucleases, including CRISPR-Cas9 and TALENs, can potentially help restore the correct gene expression patterns by targeting a defined gene or pathway, both genetically and epigenetically, with minimal off-target activity. Here, we review the implication of epigenetic machinery in NDs. We outline syndromes caused by mutations in chromatin-modifying enzymes and discuss the functional consequences of mutations in regulatory DNA in NDs. We review the approaches that allow modifying the (epi)genome, including tools based on TALENs and CRISPR-Cas9 technologies, and we highlight how these new strategies could potentially change clinical practices in the treatment of NDs. MDPI 2021-08-04 /pmc/articles/PMC8399958/ /pubmed/34451862 http://dx.doi.org/10.3390/ph14080765 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Janowski, Marcin
Milewska, Małgorzata
Zare, Peyman
Pękowska, Aleksandra
Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue
title Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue
title_full Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue
title_fullStr Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue
title_full_unstemmed Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue
title_short Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue
title_sort chromatin alterations in neurological disorders and strategies of (epi)genome rescue
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399958/
https://www.ncbi.nlm.nih.gov/pubmed/34451862
http://dx.doi.org/10.3390/ph14080765
work_keys_str_mv AT janowskimarcin chromatinalterationsinneurologicaldisordersandstrategiesofepigenomerescue
AT milewskamałgorzata chromatinalterationsinneurologicaldisordersandstrategiesofepigenomerescue
AT zarepeyman chromatinalterationsinneurologicaldisordersandstrategiesofepigenomerescue
AT pekowskaaleksandra chromatinalterationsinneurologicaldisordersandstrategiesofepigenomerescue